Cancer Diagnostics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The global cancer diagnostics market was valued at USD 23.84 Billion in 2024 , driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034 .
Cancer Diagnostics Market Overview
Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease progression.
Cancer Diagnostics Market Growth Drivers
Rising Merger and Acquisition Activities to Accelerate Market Growth
Increasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics’ extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider demographic.
Increasing Fundings and Investments to Meet Rising Cancer Diagnostics Market Demand
Growing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast period.
Cancer Diagnostics Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market Growth
The market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy’s increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market value.
Integration of Advanced Technologies to Impact the Cancer Diagnostics Market Value Positively
Artificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare sector.
Strategic Partnerships Poised to Drive Cancer Diagnostics Market Growth
The growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic solutions.
Adoption of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market Size
Next-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market.
Cancer Diagnostics Market Segmentation
"Cancer Diagnostics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
Molecular Diagnostics to Lead Market Breakup by Technology
Molecular diagnostics is expected to hold a major market share by technology, driven by advanced technologies like DNA sequencing, PCR, and cfDNA testing. As per the analysis by Expert Market Research, the global molecular diagnostics market is expected to grow at a CAGR of 8.2% during the forecast period of 2025-2034. The growing need for personalised treatment and early detection of cancer, along with the demand for more accurate and less invasive diagnostic methods, is fuelling the expansion of this segment. Molecular diagnostics offers high sensitivity and specificity, making it essential in identifying cancer at its earliest stages. With continuous advancements in genomics and biomarker discovery, this segment is expected to see substantial growth during the forecast period, revolutionising cancer detection.
Cancer Diagnostics Market Segmentation by Application to Undergo Significant Growth
Breast cancer will likely hold a substantial market share due to its high incidence and ongoing advancements in diagnostic technologies. As the most common cancer among women globally, the demand for early detection and personalised treatment plans has led to a surge in diagnostic solutions for breast cancer. As per the analysis by Expert Market Research, the global breast cancer treatment market is likely to grow at a CAGR of 10.10% during the forecast period of 2025-2034. Innovations in imaging technologies, along with molecular diagnostics, have significantly improved detection accuracy and outcomes. This segment’s dominant share is poised to continue its growth due to increasing awareness, early screening initiatives, and the rising number of breast cancer cases worldwide, ensuring sustained market demand in the coming years.
Cancer Diagnostics Market by Clinical Positioning to Witness Growth
Early detection is expected to hold a considerable share in the clinical positioning sector, owing to its critical role in improving patient outcomes and survival rates. With increasing awareness about the benefits of diagnosing cancer in its early stages, both patients and healthcare providers are prioritizing screening methods. Advancements in imaging and molecular diagnostics have enabled more accurate and timely detection, making it a vital area for market growth. As healthcare systems globally focus on preventive care and early-stage cancer detection, this segment is expected to dominate the market in the forecast period, supporting the global demand for innovative diagnostic tools.
Cancer Diagnostics Market Analysis by Region
North America is expected to hold a major share of the market driven by the region's advanced healthcare infrastructure, high investment in research and development, and increasing cancer incidence rates. The U.S., in particular, benefits from robust healthcare policies, early screening programmes, and access to cutting-edge diagnostic technologies. A strong presence of leading healthcare companies and continuous advancements in molecular diagnostics and imaging technologies further bolster the market. Additionally, the growing focus on personalised medicine and precision oncology, combined with high awareness and well-established insurance systems, supports rapid adoption of cancer diagnostics in North America, positioning it for sustained market leadership in the forecast period.
Leading Players in the Cancer Diagnostics Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F. Hoffmann-La Roche AG
Headquartered in Basel, Switzerland, F. Hoffmann-La Roche AG was established in 1896. It is a global leader in diagnostics and healthcare, offering a wide range of products in oncology diagnostics. Their portfolio includes innovative diagnostic tests for cancer biomarkers, molecular diagnostics, and liquid biopsy tests, aimed at improving early detection and treatment monitoring. In September 2024, Roche announced the expansion of its digital pathology open environment, incorporating over 20 AI algorithms from eight new collaborators. These partnerships aim to optimise the diagnostic process by assisting pathologists and researchers in detecting and diagnosing cancers more accurately. The integration of AI technologies will accelerate diagnostic workflows, improve detection rates, and increase precision in cancer diagnosis. Roche’s oncology diagnostics solutions are crucial in personalised medicine, enabling healthcare providers to tailor treatments based on individual patient needs, thereby enhancing patient outcomes and advancing cancer care.
Thermo Fisher Scientific, Inc.
Founded in 1956 and headquartered in Waltham, Massachusetts, Thermo Fisher Scientific, Inc. is a major player in the global diagnostics market. The company’s portfolio in cancer diagnostics includes advanced molecular diagnostics, next-generation sequencing (NGS) solutions, and laboratory instruments. These innovations support early detection, disease monitoring, and targeted treatment in oncology. Thermo Fisher's products empower researchers and clinicians to better understand cancer’s genetic profile, enabling the development of personalised therapies and improving patient care. Their broad range of tools plays a key role in advancing global cancer research and diagnostics.
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. BD provides comprehensive solutions in the cancer diagnostics sector, specialising in precision diagnostics, molecular testing, and flow cytometry. Their portfolio includes diagnostic instruments, reagents, and systems for oncology, enabling faster, more accurate detection and monitoring of cancer. BD's products aid in assessing tumour biomarkers, supporting both clinical and research applications. Their innovative approach is focused on enhancing diagnostic workflows and improving the accuracy of cancer detection and prognosis.
Danaher Corporation
Danaher Corporation, established in 1969 and headquartered in Washington, D.C., is a global science and technology innovator. In the cancer diagnostics market, Danaher’s portfolio includes diagnostic instruments, imaging solutions, and advanced molecular testing platforms. Its brands, such as Cepheid and Leica Biosystems, provide cutting-edge diagnostic technologies, enabling clinicians to detect cancer early and monitor treatment efficacy. With a focus on precision and efficiency, Danaher's innovations enhance oncology care by offering faster, more accurate diagnostic tools, ultimately supporting personalised cancer therapies and improving patient outcomes.
Other key players in the market include Agilent Technologies Inc., GE Healthcare, Abbott, Siemens Healthineers, Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer Inc., QIAGEN, Hologic, Inc., Myriad Genetics, Inc., Sysmex Corporation, NeoGenomics Laboratories, Inc., Foundation Medicine, Grail, Guardant, Tempus, Delfi Diagnotics, and Exact Sciences Corporation.
Key Questions Answered in the Cancer Diagnostics Market
Cancer Diagnostics Market Overview
Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease progression.
Cancer Diagnostics Market Growth Drivers
Rising Merger and Acquisition Activities to Accelerate Market Growth
Increasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics’ extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider demographic.
Increasing Fundings and Investments to Meet Rising Cancer Diagnostics Market Demand
Growing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast period.
Cancer Diagnostics Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market Growth
The market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy’s increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market value.
Integration of Advanced Technologies to Impact the Cancer Diagnostics Market Value Positively
Artificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare sector.
Strategic Partnerships Poised to Drive Cancer Diagnostics Market Growth
The growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic solutions.
Adoption of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market Size
Next-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market.
Cancer Diagnostics Market Segmentation
"Cancer Diagnostics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
- Blood-based Diagnostics
- In Vitro Diagnostics Immunoassays Histopathology Others
- Molecular Diagnostics cfDNA Testing DNA Methylation Analysis Gene Sequencing Polymerase Chain Reaction (PCR) In Situ Hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Microarrays Spectrometry Others
- Non-blood-based Diagnostics
- Imaging CT MRI PET Others
- Biopsy Comparative Analysis Solid Liquid Others
- Others
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Blood Cancers (Leukemia and Lymphoma)
- Skin Cancer (Melanoma)
- Others
- Screening
- Early Detection
- Treatment Guidance
- Treatment Response Assessment
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Molecular Diagnostics to Lead Market Breakup by Technology
Molecular diagnostics is expected to hold a major market share by technology, driven by advanced technologies like DNA sequencing, PCR, and cfDNA testing. As per the analysis by Expert Market Research, the global molecular diagnostics market is expected to grow at a CAGR of 8.2% during the forecast period of 2025-2034. The growing need for personalised treatment and early detection of cancer, along with the demand for more accurate and less invasive diagnostic methods, is fuelling the expansion of this segment. Molecular diagnostics offers high sensitivity and specificity, making it essential in identifying cancer at its earliest stages. With continuous advancements in genomics and biomarker discovery, this segment is expected to see substantial growth during the forecast period, revolutionising cancer detection.
Cancer Diagnostics Market Segmentation by Application to Undergo Significant Growth
Breast cancer will likely hold a substantial market share due to its high incidence and ongoing advancements in diagnostic technologies. As the most common cancer among women globally, the demand for early detection and personalised treatment plans has led to a surge in diagnostic solutions for breast cancer. As per the analysis by Expert Market Research, the global breast cancer treatment market is likely to grow at a CAGR of 10.10% during the forecast period of 2025-2034. Innovations in imaging technologies, along with molecular diagnostics, have significantly improved detection accuracy and outcomes. This segment’s dominant share is poised to continue its growth due to increasing awareness, early screening initiatives, and the rising number of breast cancer cases worldwide, ensuring sustained market demand in the coming years.
Cancer Diagnostics Market by Clinical Positioning to Witness Growth
Early detection is expected to hold a considerable share in the clinical positioning sector, owing to its critical role in improving patient outcomes and survival rates. With increasing awareness about the benefits of diagnosing cancer in its early stages, both patients and healthcare providers are prioritizing screening methods. Advancements in imaging and molecular diagnostics have enabled more accurate and timely detection, making it a vital area for market growth. As healthcare systems globally focus on preventive care and early-stage cancer detection, this segment is expected to dominate the market in the forecast period, supporting the global demand for innovative diagnostic tools.
Cancer Diagnostics Market Analysis by Region
North America is expected to hold a major share of the market driven by the region's advanced healthcare infrastructure, high investment in research and development, and increasing cancer incidence rates. The U.S., in particular, benefits from robust healthcare policies, early screening programmes, and access to cutting-edge diagnostic technologies. A strong presence of leading healthcare companies and continuous advancements in molecular diagnostics and imaging technologies further bolster the market. Additionally, the growing focus on personalised medicine and precision oncology, combined with high awareness and well-established insurance systems, supports rapid adoption of cancer diagnostics in North America, positioning it for sustained market leadership in the forecast period.
Leading Players in the Cancer Diagnostics Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F. Hoffmann-La Roche AG
Headquartered in Basel, Switzerland, F. Hoffmann-La Roche AG was established in 1896. It is a global leader in diagnostics and healthcare, offering a wide range of products in oncology diagnostics. Their portfolio includes innovative diagnostic tests for cancer biomarkers, molecular diagnostics, and liquid biopsy tests, aimed at improving early detection and treatment monitoring. In September 2024, Roche announced the expansion of its digital pathology open environment, incorporating over 20 AI algorithms from eight new collaborators. These partnerships aim to optimise the diagnostic process by assisting pathologists and researchers in detecting and diagnosing cancers more accurately. The integration of AI technologies will accelerate diagnostic workflows, improve detection rates, and increase precision in cancer diagnosis. Roche’s oncology diagnostics solutions are crucial in personalised medicine, enabling healthcare providers to tailor treatments based on individual patient needs, thereby enhancing patient outcomes and advancing cancer care.
Thermo Fisher Scientific, Inc.
Founded in 1956 and headquartered in Waltham, Massachusetts, Thermo Fisher Scientific, Inc. is a major player in the global diagnostics market. The company’s portfolio in cancer diagnostics includes advanced molecular diagnostics, next-generation sequencing (NGS) solutions, and laboratory instruments. These innovations support early detection, disease monitoring, and targeted treatment in oncology. Thermo Fisher's products empower researchers and clinicians to better understand cancer’s genetic profile, enabling the development of personalised therapies and improving patient care. Their broad range of tools plays a key role in advancing global cancer research and diagnostics.
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. BD provides comprehensive solutions in the cancer diagnostics sector, specialising in precision diagnostics, molecular testing, and flow cytometry. Their portfolio includes diagnostic instruments, reagents, and systems for oncology, enabling faster, more accurate detection and monitoring of cancer. BD's products aid in assessing tumour biomarkers, supporting both clinical and research applications. Their innovative approach is focused on enhancing diagnostic workflows and improving the accuracy of cancer detection and prognosis.
Danaher Corporation
Danaher Corporation, established in 1969 and headquartered in Washington, D.C., is a global science and technology innovator. In the cancer diagnostics market, Danaher’s portfolio includes diagnostic instruments, imaging solutions, and advanced molecular testing platforms. Its brands, such as Cepheid and Leica Biosystems, provide cutting-edge diagnostic technologies, enabling clinicians to detect cancer early and monitor treatment efficacy. With a focus on precision and efficiency, Danaher's innovations enhance oncology care by offering faster, more accurate diagnostic tools, ultimately supporting personalised cancer therapies and improving patient outcomes.
Other key players in the market include Agilent Technologies Inc., GE Healthcare, Abbott, Siemens Healthineers, Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer Inc., QIAGEN, Hologic, Inc., Myriad Genetics, Inc., Sysmex Corporation, NeoGenomics Laboratories, Inc., Foundation Medicine, Grail, Guardant, Tempus, Delfi Diagnotics, and Exact Sciences Corporation.
Key Questions Answered in the Cancer Diagnostics Market
- What was the global cancer diagnostics market value in 2024?
- What is the cancer diagnostics market forecast outlook for 2025-2034?
- What is market segmentation based on technology?
- How is the market segmented based on application?
- How is the market segmented based on clinical positioning?
- What are the major factors aiding the global cancer diagnostics market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major cancer diagnostics market trends?
- Which technology will lead the market segment?
- Which application will lead the market segment?
- Which clinical positioning will lead the market segment?
- Who are the key players involved in the cancer diagnostics market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cancer Diagnostics Market Overview
- 3.1 Global Cancer Diagnostics Market Historical Value (2018-2024)
- 3.2 Global Cancer Diagnostics Market Forecast Value (2018-2024)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Cancer Diagnostics Market Landscape*
- 5.1 Global Cancer Diagnostics Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Cancer Diagnostics Market: Product Landscape
- 5.2.1 Analysis by Technology
- 5.2.2 Analysis by Indication
- 6 Global Cancer Diagnostics Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Cancer Diagnostics Market Segmentation (218-2034)
- 7.1 Global Cancer Diagnostics Market (2018-2034) by Technology
- 7.1.1 Market Overview
- 7.1.2 Blood-based Diagnostics
- 7.1.2.1 In Vitro Diagnostics
- 7.1.2.1.1 Immunoassays
- 7.1.2.1.2 Histopathology
- 7.1.2.1.3 Others
- 7.1.2.2 Molecular Diagnostics
- 7.1.2.2.1 cfDNA Testing
- 7.1.2.2.2 DNA Methylation Analysis
- 7.1.2.2.3 Gene Sequencing
- 7.1.2.2.4 Polymerase Chain Reaction (PCR)
- 7.1.2.2.5 In Situ Hybridization
- 7.1.2.2.6 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 7.1.2.2.7 Microarrays
- 7.1.2.2.8 Spectrometry
- 7.1.2.2.9 Others
- 7.1.3 Non-blood-based Diagnostics
- 7.1.3.1 Imaging
- 7.1.3.1.1 CT
- 7.1.3.1.2 MRI
- 7.1.3.1.3 PET
- 7.1.3.1.4 Others
- 7.1.3.2 Biopsy
- 7.1.3.2.1 Comparative Analysis
- 7.1.3.2.2 Solid
- 7.1.3.2.3 Liquid
- 7.1.3.2.4 Others
- 7.1.4 Others
- 7.2 Global Cancer Diagnostics Market (2018-2034) by Indication
- 7.2.1 Market Overview
- 7.2.2 Breast Cancer
- 7.2.3 Lung Cancer
- 7.2.4 Colorectal Cancer
- 7.2.5 Prostate Cancer
- 7.2.6 Cervical Cancer
- 7.2.7 Blood Cancers (Leukemia and Lymphoma)
- 7.2.8 Skin Cancer (Melanoma)
- 7.2.9 Others
- 7.3 Global Cancer Diagnostics Market (2018-2034) by Clinical Positioning
- 7.3.1 Market Overview
- 7.3.2 Screening
- 7.3.3 Early Detection
- 7.3.4 Treatment Guidance
- 7.3.5 Treatment Response Assessment
- 7.4 Global Cancer Diagnostics Market (2018-2034) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Cancer Diagnostics Market (218-2034)
- 8.1 North America Cancer Diagnostics Market (2018-2034) by Technology
- 8.1.1 Market Overview
- 8.1.1.1 In Vitro Diagnostics
- 8.1.1.1.1 Immunoassays
- 8.1.1.1.2 Histopathology
- 8.1.1.1.3 Others
- 8.1.1.2 Molecular Diagnostics
- 8.1.1.2.1 cfDNA Testing
- 8.1.1.2.2 DNA Methylation Analysis
- 8.1.1.2.3 Gene Sequencing
- 8.1.1.2.4 Polymerase Chain Reaction (PCR)
- 8.1.1.2.5 In Situ Hybridization
- 8.1.1.2.6 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 8.1.1.2.7 Microarrays
- 8.1.1.2.8 Spectrometry
- 8.1.1.2.9 Others
- 8.1.2 Non-blood-based Diagnostics
- 8.1.2.1 Imaging
- 8.1.2.1.1 CT
- 8.1.2.1.2 MRI
- 8.1.2.1.3 PET
- 8.1.2.1.4 Others
- 8.1.2.2 Biopsy
- 8.1.2.2.1 Comparative Analysis
- 8.1.2.2.2 Solid
- 8.1.2.2.3 Liquid
- 8.1.2.2.4 Others
- 8.1.3 Others
- 8.2 North America Cancer Diagnostics Market (2018-2034) by Indication
- 8.2.1 Market Overview
- 8.2.2 Breast Cancer
- 8.2.3 Lung Cancer
- 8.2.4 Colorectal Cancer
- 8.2.5 Prostate Cancer
- 8.2.6 Cervical Cancer
- 8.2.7 Blood Cancers (Leukemia and Lymphoma)
- 8.2.8 Skin Cancer (Melanoma)
- 8.2.9 Others
- 8.3 North America Cancer Diagnostics Market (2018-2034) by Clinical Positioning
- 8.3.1 Market Overview
- 8.3.2 Screening
- 8.3.3 Early Detection
- 8.3.4 Treatment Guidance
- 8.3.5 Treatment Response Assessment
- 8.4 North America Cancer Diagnostics Market (2018-2034) by Country
- 8.4.1 United States of America
- 8.4.1.1 United States of America Cancer Diagnostics Market (2018-2034) by Technology
- 8.4.1.2 United States of America Cancer Diagnostics Market Size, by Technology
- 8.4.2 Canada
- 8.4.2.1 Canada Cancer Diagnostics Market (2018-2034) by Technology
- 9 Europe Cancer Diagnostics Market (218-2034)
- 9.1 Europe Cancer Diagnostics Market (2018-2034) by Technology
- 9.1.1 Market Overview
- 9.1.1.1 In Vitro Diagnostics
- 9.1.1.1.1 Immunoassays
- 9.1.1.1.2 Histopathology
- 9.1.1.1.3 Others
- 9.1.1.2 Molecular Diagnostics
- 9.1.1.2.1 cfDNA Testing
- 9.1.1.2.2 DNA Methylation Analysis
- 9.1.1.2.3 Gene Sequencing
- 9.1.1.2.4 Polymerase Chain Reaction (PCR)
- 9.1.1.2.5 In Situ Hybridization
- 9.1.1.2.6 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 9.1.1.2.7 Microarrays
- 9.1.1.2.8 Spectrometry
- 9.1.1.2.9 Others
- 9.1.2 Non-blood-based Diagnostics
- 9.1.2.1 Imaging
- 9.1.2.1.1 CT
- 9.1.2.1.2 MRI
- 9.1.2.1.3 PET
- 9.1.2.1.4 Others
- 9.1.2.2 Biopsy
- 9.1.2.2.1 Comparative Analysis
- 9.1.2.2.2 Solid
- 9.1.2.2.3 Liquid
- 9.1.2.2.4 Others
- 9.1.3 Others
- 9.2 Europe Cancer Diagnostics Market (2018-2034) by Indication
- 9.2.1 Market Overview
- 9.2.2 Breast Cancer
- 9.2.3 Lung Cancer
- 9.2.4 Colorectal Cancer
- 9.2.5 Prostate Cancer
- 9.2.6 Cervical Cancer
- 9.2.7 Blood Cancers (Leukemia and Lymphoma)
- 9.2.8 Skin Cancer (Melanoma)
- 9.2.9 Others
- 9.3 Europe Cancer Diagnostics Market (2018-2034) by Clinical Positioning
- 9.3.1 Market Overview
- 9.3.2 Screening
- 9.3.3 Early Detection
- 9.3.4 Treatment Guidance
- 9.3.5 Treatment Response Assessment
- 9.4 Europe Cancer Diagnostics Market (2018-2034) by Country
- 9.4.1 United Kingdom
- 9.4.1.1 United Kingdom Cancer Diagnostics Market (2018-2034) by Technology
- 9.4.2 Germany
- 9.4.2.1 Germany Cancer Diagnostics Market (2018-2034) by Technology
- 9.4.3 France
- 9.4.3.1 France Cancer Diagnostics Market (2018-2034) by Technology
- 9.4.4 Italy
- 9.4.4.1 Italy Cancer Diagnostics Market (2018-2034) by Technology
- 9.4.5 Others
- 10 Asia Pacific Cancer Diagnostics Market (218-2034)
- 10.1 Asia Pacific Cancer Diagnostics Market (2018-2034) by Technology
- 10.1.1 Market Overview
- 10.1.1.1 In Vitro Diagnostics
- 10.1.1.1.1 Immunoassays
- 10.1.1.1.2 Histopathology
- 10.1.1.1.3 Others
- 10.1.1.2 Molecular Diagnostics
- 10.1.1.2.1 cfDNA Testing
- 10.1.1.2.2 DNA Methylation Analysis
- 10.1.1.2.3 Gene Sequencing
- 10.1.1.2.4 Polymerase Chain Reaction (PCR)
- 10.1.1.2.5 In Situ Hybridization
- 10.1.1.2.6 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 10.1.1.2.7 Microarrays
- 10.1.1.2.8 Spectrometry
- 10.1.1.2.9 Others
- 10.1.2 Non-blood-based Diagnostics
- 10.1.2.1 Imaging
- 10.1.2.1.1 CT
- 10.1.2.1.2 MRI
- 10.1.2.1.3 PET
- 10.1.2.1.4 Others
- 10.1.2.2 Biopsy
- 10.1.2.2.1 Comparative Analysis
- 10.1.2.2.2 Solid
- 10.1.2.2.3 Liquid
- 10.1.2.2.4 Others
- 10.1.3 Others
- 10.2 Asia Pacific Cancer Diagnostics Market (2018-2034) by Indication
- 10.2.1 Market Overview
- 10.2.2 Breast Cancer
- 10.2.3 Lung Cancer
- 10.2.4 Colorectal Cancer
- 10.2.5 Prostate Cancer
- 10.2.6 Cervical Cancer
- 10.2.7 Blood Cancers (Leukemia and Lymphoma)
- 10.2.8 Skin Cancer (Melanoma)
- 10.2.9 Others
- 10.3 Asia Pacific Cancer Diagnostics Market (2018-2034) by Clinical Positioning
- 10.3.1 Market Overview
- 10.3.2 Screening
- 10.3.3 Early Detection
- 10.3.4 Treatment Guidance
- 10.3.5 Treatment Response Assessment
- 10.4 Asia Pacific Cancer Diagnostics Market (2018-2034) by Country
- 10.4.1 China
- 10.4.1.1 China Cancer Diagnostics Market (2018-2034) by Technology
- 10.4.2 Japan
- 10.4.2.1 Japan Cancer Diagnostics Market (2018-2034) by Technology
- 10.4.3 India
- 10.4.3.1 India Cancer Diagnostics Market (2018-2034) by Technology
- 10.4.4 ASEAN
- 10.4.4.1 ASEAN Cancer Diagnostics Market (2018-2034) by Technology
- 10.4.5 Australia
- 10.4.5.1 Australia Cancer Diagnostics Market (2018-2034) by Technology
- 10.4.6 Others
- 11 Latin America Cancer Diagnostics Market (218-2034)
- 11.1 Latin America Cancer Diagnostics Market (2018-2034) by Technology
- 11.1.1 Market Overview
- 11.1.1.1 In Vitro Diagnostics
- 11.1.1.1.1 Immunoassays
- 11.1.1.1.2 Histopathology
- 11.1.1.1.3 Others
- 11.1.1.2 Molecular Diagnostics
- 11.1.1.2.1 cfDNA Testing
- 11.1.1.2.2 DNA Methylation Analysis
- 11.1.1.2.3 Gene Sequencing
- 11.1.1.2.4 Polymerase Chain Reaction (PCR)
- 11.1.1.2.5 In Situ Hybridization
- 11.1.1.2.6 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 11.1.1.2.7 Microarrays
- 11.1.1.2.8 Spectrometry
- 11.1.1.2.9 Others
- 11.1.2 Non-blood-based Diagnostics
- 11.1.2.1 Imaging
- 11.1.2.1.1 CT
- 11.1.2.1.2 MRI
- 11.1.2.1.3 PET
- 11.1.2.1.4 Others
- 11.1.2.2 Biopsy
- 11.1.2.2.1 Comparative Analysis
- 11.1.2.2.2 Solid
- 11.1.2.2.3 Liquid
- 11.1.2.2.4 Others
- 11.1.3 Others
- 11.2 Latin America Cancer Diagnostics Market (2018-2034) by Indication
- 11.2.1 Market Overview
- 11.2.2 Breast Cancer
- 11.2.3 Lung Cancer
- 11.2.4 Colorectal Cancer
- 11.2.5 Prostate Cancer
- 11.2.6 Cervical Cancer
- 11.2.7 Blood Cancers (Leukemia and Lymphoma)
- 11.2.8 Skin Cancer (Melanoma)
- 11.2.9 Others
- 11.3 Latin America Cancer Diagnostics Market (2018-2034) by Clinical Positioning
- 11.3.1 Market Overview
- 11.3.2 Screening
- 11.3.3 Early Detection
- 11.3.4 Treatment Guidance
- 11.3.5 Treatment Response Assessment
- 11.4 Latin America Cancer Diagnostics Market (2018-2034) by Country
- 11.4.1 Brazil
- 11.4.1.1 Brazil Cancer Diagnostics Market (2018-2034) by Technology
- 11.4.2 Argentina
- 11.4.2.1 Argentina Cancer Diagnostics Market (2018-2034) by Technology
- 11.4.3 Mexico
- 11.4.3.1 Mexico Cancer Diagnostics Market (2018-2034) by Technology
- 11.4.4 Others
- 12 Middle East and Africa Cancer Diagnostics Market (218-2034)
- 12.1 Middle East and Africa Cancer Diagnostics Market (2018-2034) by Technology
- 12.1.1 Market Overview
- 12.1.1.1 In Vitro Diagnostics
- 12.1.1.1.1 Immunoassays
- 12.1.1.1.2 Histopathology
- 12.1.1.1.3 Others
- 12.1.1.2 Molecular Diagnostics
- 12.1.1.2.1 cfDNA Testing
- 12.1.1.2.2 DNA Methylation Analysis
- 12.1.1.2.3 Gene Sequencing
- 12.1.1.2.4 Polymerase Chain Reaction (PCR)
- 12.1.1.2.5 In Situ Hybridization
- 12.1.1.2.6 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 12.1.1.2.7 Microarrays
- 12.1.1.2.8 Spectrometry
- 12.1.1.2.9 Others
- 12.1.2 Non-blood-based Diagnostics
- 12.1.2.1 Imaging
- 12.1.2.1.1 CT
- 12.1.2.1.2 MRI
- 12.1.2.1.3 PET
- 12.1.2.1.4 Others
- 12.1.2.2 Biopsy
- 12.1.2.2.1 Comparative Analysis
- 12.1.2.2.2 Solid
- 12.1.2.2.3 Liquid
- 12.1.2.2.4 Others
- 12.1.3 Others
- 12.2 Middle East and Africa Cancer Diagnostics Market (2018-2034) by Indication
- 12.2.1 Market Overview
- 12.2.2 Breast Cancer
- 12.2.3 Lung Cancer
- 12.2.4 Colorectal Cancer
- 12.2.5 Prostate Cancer
- 12.2.6 Cervical Cancer
- 12.2.7 Blood Cancers (Leukemia and Lymphoma)
- 12.2.8 Skin Cancer (Melanoma)
- 12.2.9 Others
- 12.3 Middle East and Africa Cancer Diagnostics Market (2018-2034) by Clinical Positioning
- 12.3.1 Market Overview
- 12.3.2 Screening
- 12.3.3 Early Detection
- 12.3.4 Treatment Guidance
- 12.3.5 Treatment Response Assessment
- 12.4 Middle East and Africa Cancer Diagnostics Market (2018-2034) by Country
- 12.4.1 Saudi Arabia
- 12.4.1.1 Saudi Arabia Cancer Diagnostics Market (2018-2034) by Technology
- 12.4.2 United Arab Emirates
- 12.4.2.1 United Arab Emirates Cancer Diagnostics Market (2018-2034) by Technology
- 12.4.3 Nigeria
- 12.4.3.1 Nigeria Cancer Diagnostics Market (2018-2034) by Technology
- 12.4.4 South Africa
- 12.4.4.1 South Africa Cancer Diagnostics Market (2018-2034) by Technology
- 12.4.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Grant Analysis
- 15.1 Analysis by Year
- 15.2 Analysis by Amount Awarded
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Grant Product
- 15.5 Analysis by Funding Institute
- 15.6 Analysis by Departments
- 15.7 Analysis by Recipient Organization
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Initiatives
- 17.3 Analysis by Joint Ventures
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Market Share Analysis, By Region (Top 5 Companies)
- 18.1.1 Market Share Analysis: Global
- 18.1.2 Market Share Analysis: North America
- 18.1.3 Market Share Analysis: Europe
- 18.1.4 Market Share Analysis: Asia Pacific
- 18.1.5 Market Share Analysis: Others
- 18.2 Agilent Technologies, Inc.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News and Development
- 18.2.5 Certifications
- 18.3 F. Hoffmann-La Roche AG
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News and Development
- 18.3.5 Certifications
- 18.4 Thermo Fisher Scientific, Inc.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News and Development
- 18.4.5 Certifications
- 18.5 Becton, Dickinson and Company
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News and Development
- 18.5.5 Certifications
- 18.6 Danaher Corporation
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News and Development
- 18.6.5 Certifications
- 18.7 GE Healthcare
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News and Development
- 18.7.5 Certifications
- 18.8 Abbott
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News and Development
- 18.8.5 Certifications
- 18.9 Siemens Healthineers
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News and Development
- 18.9.5 Certifications
- 18.10 Bio-Rad Laboratories, Inc.
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Company News and Development
- 18.10.5 Certifications
- 18.11 Illumina, Inc.
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Company News and Development
- 18.11.5 Certifications
- 18.12 PerkinElmer Inc.
- 18.12.1 Financial Analysis
- 18.12.2 Product Portfolio
- 18.12.3 Demographic Reach and Achievements
- 18.12.4 Company News and Development
- 18.12.5 Certifications
- 18.13 QIAGEN
- 18.13.1 Financial Analysis
- 18.13.2 Product Portfolio
- 18.13.3 Demographic Reach and Achievements
- 18.13.4 Company News and Development
- 18.13.5 Certifications
- 18.14 Hologic, Inc.
- 18.14.1 Financial Analysis
- 18.14.2 Product Portfolio
- 18.14.3 Demographic Reach and Achievements
- 18.14.4 Company News and Development
- 18.14.5 Certifications
- 18.15 Myriad Genetics, Inc.
- 18.15.1 Financial Analysis
- 18.15.2 Product Portfolio
- 18.15.3 Demographic Reach and Achievements
- 18.15.4 Company News and Development
- 18.15.5 Certifications
- 18.16 Sysmex Corporation
- 18.16.1 Financial Analysis
- 18.16.2 Product Portfolio
- 18.16.3 Demographic Reach and Achievements
- 18.16.4 Company News and Development
- 18.16.5 Certifications
- 18.17 NeoGenomics Laboratories, Inc.
- 18.17.1 Financial Analysis
- 18.17.2 Product Portfolio
- 18.17.3 Demographic Reach and Achievements
- 18.17.4 Company News and Development
- 18.17.5 Certifications
- 18.18 Foundation Medicine
- 18.18.1 Financial Analysis
- 18.18.2 Product Portfolio
- 18.18.3 Demographic Reach and Achievements
- 18.18.4 Company News and Development
- 18.18.5 Certifications
- 18.19 Grail
- 18.19.1 Financial Analysis
- 18.19.2 Product Portfolio
- 18.19.3 Demographic Reach and Achievements
- 18.19.4 Company News and Development
- 18.19.5 Certifications
- 18.20 Guardant
- 18.20.1 Financial Analysis
- 18.20.2 Product Portfolio
- 18.20.3 Demographic Reach and Achievements
- 18.20.4 Company News and Development
- 18.20.5 Certifications
- 18.21 Tempus
- 18.21.1 Financial Analysis
- 18.21.2 Product Portfolio
- 18.21.3 Demographic Reach and Achievements
- 18.21.4 Company News and Development
- 18.21.5 Certifications
- 18.22 Delfi Diagnotics
- 18.22.1 Financial Analysis
- 18.22.2 Product Portfolio
- 18.22.3 Demographic Reach and Achievements
- 18.22.4 Company News and Development
- 18.22.5 Certifications
- 18.23 Exact Sciences Corporation
- 18.23.1 Financial Analysis
- 18.23.2 Product Portfolio
- 18.23.3 Demographic Reach and Achievements
- 18.23.4 Company News and Development
- 18.23.5 Certifications
- 19 Global Cancer Diagnostics Market – Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
